Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
出版年份 2022 全文链接
标题
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
作者
关键词
-
出版物
LANCET INFECTIOUS DISEASES
Volume 22, Issue 6, Pages 791-801
出版商
Elsevier BV
发表日期
2022-04-01
DOI
10.1016/s1473-3099(22)00140-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
- (2021) Otavio T Ranzani et al. Lancet Respiratory Medicine
- Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
- (2021) Xinhua Chen et al. Lancet Global Health
- Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines
- (2021) Joseph A. Lewnard et al. EPIDEMIOLOGY
- Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
- (2021) Frauke Muecksch et al. IMMUNITY
- Is one vaccine dose enough if you’ve had COVID? What the science says
- (2021) Elie Dolgin NATURE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021
- (2021) Alyson M. Cavanaugh et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors
- (2021) Matthew Frieman et al. EBioMedicine
- Clinical characteristics and risk factors for death among hospitalised children and adolescents with COVID-19 in Brazil: an analysis of a nationwide database
- (2021) Eduardo A Oliveira et al. Lancet Child & Adolescent Health
- Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
- (2021) Wey Wen Lim et al. Lancet Microbe
- Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
- (2021) Caifang Zheng et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar
- (2021) Laith J. Abu-Raddad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
- (2021) Srinivasa Vittal Katikireddi et al. LANCET
- China’s COVID vaccines have been crucial — now immunity is waning
- (2021) Smriti Mallapaty NATURE
- Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
- (2021) Koen B. Pouwels et al. NATURE MEDICINE
- Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
- (2021) Adrienn Angyal et al. Lancet Microbe
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
- (2009) Peter C. Austin COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started